Psoriasis - Epidemiology Forecast To 2023

Wednesday, November 16, 2016 Drug News J E 4

LONDON, Nov. 16, 2016 /PRNewswire/ -- DelveInsight "Psoriasis - Epidemiology Forecast To 2023" provides an overview of the epidemiology trends of Psoriasis in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Psoriasis prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with the Psoriasis. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by DelveInsight team of industry experts. Please note: This report requires 5-7 business days to complete. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.Scope of the Report- The Report includes the prevalent population and how will it change over the next eight years.- Prevalent or incident cases segmented by age and sex.- Coverage of key Psoriasis subpopulations and its prevalent or incident cases- The key differences in epidemiology patterns across the seven market segmentsKey Coverage and Benefits- The report will help in developing business strategies by understanding the trends shaping and driving the global Psoriasis market. - Identifying prevalent patient populations as well as risk factors in the global Psoriasis market will help to improve product design, pricing, and launch plans.- Organize sales and marketing efforts by identifying the best opportunities for Psoriasis therapeutics in each of the markets covered.Download the full report: ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers For more information: Sarah Smith Research Advisor at Email:  Tel: +44 208 816 85 48 Website:

To view the original version on PR Newswire, visit:

SOURCE ReportBuyer



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
How These Biotech Stocks are Faring? -- Alexion Ph...
Nuvo Pharmaceuticals™ Inc. Appoints Jesse Ledger a...